In sickle cell disease, sickle erythrocyte (SSRBC) interacts with endothelial cells, leukocytes, and platelets, and activates coagulation and inflammation, promoting vessel obstruction, which leads to serious life-threatening complications, including acute painful crises and irreversible damage to multiple organs. The mitogen-activated protein kinase, ERK1/2, is abnormally activated in SSRBCs. However, the therapeutic potential of SSRBC ERK1/2 inactivation has never been investigated. I tested four different inhibitors of MEK1/2 (MEK), the kinase that activates ERK1/2, in a model of human SSRBC adhesion to TNFa-activated endothelial cells (ECs). SSRBC MEK inhibition abrogated adhesion to non-activated and TNFaactivated ECs to levels below baseline SSRBC adhesion to non-activated ECs in vitro. SSRBC MEK inhibition also prevented SSRBCs from activating naïve neutrophils to adhere to endothelium. To determine the effect of MEK inhibitors on SSRBC adherence in vivo, sham-treated or MEK inhibitor-treated SSRBCs were infused to nude mice previously treated with TNFa. Sham-treated SSRBCs displayed marked adhesion and occlusion of enflamed vessels, both small and large. However, SSRBC treatment with MEK inhibitors ex vivo showed poor SSRBC adhesion to enflamed vessels with no visible vasoocclusion in vivo. In addition, MEK inhibitor treatment of SSRBCs reduced SSRBC organ trapping and increased the number of SSRBCs circulating in bloodstream. Thus, these data suggest that SSRBC ERK1/2 plays potentially a critical role in sickle pathogenesis, and that MEK inhibitors may represent a valuable intervention for acute sickle cell crises.
Introduction
In sickle cell disease (SCD), sickle red blood cells (SSRBCs) have been postulated to play a central role in vasoocclusion by adhering to the endothelium, leukocytes and platelets in capillaries and small vessels, and activating coagulation and inflammation. Vasoocclusion impairs blood flow leading to acute painful vasoocclusive crises ''pain crises'' and ischemic organ and tissue damage [1] [2] [3] [4] [5] [6] .
To date, investigators have targeted SSRBCs and explored multiple approaches to treating acute vasoocclusive crises. Therapies that focus on ameliorating SSRBC dehydration [7] [8] [9] [10] [11] , interfering with chemical-physical processes during erythrocyte-endothelial adhesion events [12] , or targeting RBC adhesion molecules [13] [14] [15] to prevent RBC-endothelial cell (EC) interactions have shown little to no therapeutic benefit. Nevertheless, despite the known contribution of SSRBC adhesiveness to vasoocclusion, we lack treatments that specifically target intracellular signaling mechanisms critical for SSRBC adhesion [1, 14, [16] [17] [18] . An in-depth understanding of signaling pathways in SSRBCs that mediate adhesion at both biochemical and physiological levels will be required to successfully exploit these pathways for therapeutic purposes and to develop efficacious pathway-selective drugs with minimal side effects.
We have recently discovered that the mitogen-activated protein kinase (MAPK), ERK1/2, is pathophysiologically activated in SSRBCs, but not in normal RBCs [16] [17] [18] . Patients with SCD manifest chronic and acute activation of inflammation, as evidenced by a statistically significant and distinct rise in plasma levels of several pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin 1beta (IL-1b), IL-4, IL-6, IL-8 and interferon gamma (IFNc) either at steady state or during painful crisis [19] [20] [21] . Because increased proinflammatory cytokines can up-regulate endothelial expression of ligands for red blood cell adhesion molecules, it remains unknown whether inhibition of ERK1/2 activation in SSRBCs has therapeutic benefits in reducing SSRBC adhesion and vasoocclusion in the presence of inflammation in vivo. Therefore, I investigated the therapeutic potential of SSRBC ERK1/2 inactivation using inhibitors of MEK1/2 (MEK), the kinase that activates ERK1/ 2, to inhibit both human SSRBC adhesion to TNFa-activated ECs and SSRBC's ability to activate neutrophil adhesion in vitro, and reduce vasoocclusion in vivo. These studies were undertaken because MEK inhibitors have been developed for human use [22] [23] [24] [25] , and the MEK inhibitor, trametinib (GSK1120212), has been recently approved by the U.S. Food and Drug Administration (FDA) for treatment of melanoma [24, 25] . Thus, my studies may lead to rapid development of existing MEK inhibitors as a novel therapeutic approach for acute sickle cell crises.
Materials and Methods

Endothelial cells
Human umbilical vein endothelial cells (HUVECs, ATCC), the murine endothelial cell line EOMA (ATCC, Manassas, VA), which exhibits properties characteristic of microvascular endothelial cells, and human dermal microvascular endothelial cells (HMVECs-d) (Lonza, Walkersville, MD) were grown as monolayers in EBM2 medium (Clonetics, Walkersville, MD) supplemented with EGM2 (Clonetics) [14, 17] . For in vitro flow chamber adhesion experiments, ECs were cultured until they reached confluence on clear glass slides pre-coated with 2% gelatin.
Collection, preparation and treatment of RBCs
Blood samples obtained from human participants has been approved by Duke University's Institutional Review Board (IRB), and written informed consent has been obtained from the participants. Blood samples were obtained from adult SCD patients, 52% of whom were male, and from adult healthy donors. SCD patients were of age between 21 and 69 years old with a mean age of 38.563 years old. All SCD patients had not been transfused for at least three months and had not experienced acute vasoocclusive crises for three weeks, and half of these patients were on hydroxyurea. Blood samples were collected and packed RBCs were separated as previously described in detail [17] . Packed RBCs were treated with various reagents to affect protein phosphorylation. RBCs were treated at 37uC for 1 h with one of the following reagents: 100 nM of the MEK inhibitor U0126 (Calbiochem, La Jolla, CA); 100 nM of the MEK inhibitor RDEA119 (CGeneTech, Inc., Indianapolis, IN); 100 nM of the MEK inhibitor trametinib (GSK1120212) (Active Biochemicals Co., Wanchai, Hong Kong); 100 nM of the MEK inhibitor AZD6244 (Selleckchem, Houston, TX); and 10 mM of the tyrosine kinase inhibitor damnacanthal (Enzo Life Sciences International, Inc., Plymouth Meeting, PA). Sham-treated RBCs were incubated with the same buffer and vehicle but without the active agent. Treated RBCs were washed 5 times with 4 ml PBS with Ca 2+ and Mg 2+ . In some in vitro and in vivo adhesion studies, RBCs were fluorescently labeled as described previously in detail [14, 17, 26] .
Neutrophil separation and activation of adhesion by SSRBCs
Separation of peripheral blood mononuclear cells (PBMCs) from neutrophils and red cells from blood from healthy donors was performed as previously described in detail [16] . Pellets composed of neutrophils and RBCs were very gently washed once with PBS to avoid activation of neutrophils. Cells were gently re-suspended in PBS and mixed with an equal volume of 3% dextran. Tubes were set upright for 20 minutes at room temperature. Neutrophilrich upper layer was collected, RBCs contaminating neutrophils were lysed with RBC lysis buffer, and neutrophils were then washed and fluorescently labeled. In parallel, packed RBCs were sham-treated or treated with a MEK inhibitor, then extensively washed prior to co-incubation for 30 min with fluorescencelabeled PMNs and performance of PMN adhesion assays as described previously [14, 16] .
In some experiments, HUVECs treated or not with 10 ng/ml recombinant human TNFa (Sigma-Aldrich, St. Louis, MO) for 4 h, were co-incubated for 30 min at 37uC with washed shamtreated or U0126-treated RBCs. HUVECs were then washed extensively to remove non-adherent RBCs prior to PMN adhesion assays.
In vitro flow chamber adhesion assays Adherent HUVECs, HMVECs-d or EOMA cells were nontreated or treated with 10 ng/ml recombinant human TNFa for 4 h at 37uC. ECs were then washed three times with 20 ml PBS prior to adhesion assays. RBC or PMN adhesion to washed nontreated or TNFa-treated ECs was assayed in graduated height flow chambers as described previously in detail [14] .
Mice
Animal work was approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University. All animal experiments were carried out in strict accordance with and following the National Institutes of Health (NIH) guidelines and recommendations for the Care and Use of Laboratory Animals. The protocol was approved by the Committee on the Ethics of Animal Experiments of Duke University (Permit Number: A023-12-01). All surgery was performed under anesthesia by intraperitoneal injection of 100 mg/kg of ketamine (Abbott Laboratory, Chicago, IL) and 10 mg/kg of xylazine (Bayer, Shawnee Mission, KS), and all efforts were made to minimize suffering. Female athymic homozygous nude (nu2/nu2) mice, 8-12 weeks of age, were bred at Duke University and housed at the vivarium at Duke University.
Window chamber surgery, RBC infusion and intravital microscopy
Dorsal skin-fold window chamber surgery was performed on anesthetized nude mice as described previously [1, 17, [27] [28] [29] . Animals were used three days following surgery. To determine the therapeutic potential of SSRBC ERK1/2 inactivation in vivo, nude mice with dorsal skin-fold window chambers were first injected intraperitoneal with 500 ng murine recombinant TNFa (Peprotech, Rocky Hill, NJ), to induce inflammation. Four hours later, animals were anesthetized as previously described [17] , then infused with sham-treated or MEK inhibitor-treated Dil-labeled human SSRBCs (300 ml, hematocrit [Hct] 50% in saline). All infusions were through the dorsal tail vein. Intravital microscopy through the dorsal skin-fold implants was conducted as described before in detail [17] . SSRBC adhesion and blood flow dynamics were observed in subdermal vessels using 106 and 206 magnifications, and at least 180 venule segments were videotaped for a period of at least 60 minutes.
Human SSRBC adhesion was quantified on still images by measuring the fluorescence intensity (pixels) of adherent fluorescently labeled SSRBCs using ImageJ software downloaded from the NIH website. The values abtained from the vessels analyzed in the accompanying videos were averaged among groups of animals (n = 5) to obtain mean fluorescence intensity and for statistical analysis. The data are presented as the fluorescence intensity of adherent SSRBCs (pixels). The percentage of vessels occupied by adherent SSRBCs was calculated by dividing the number of vessels (all vessels, small and large) supporting adherent SSRBCs by the total number of vessels recorded, then averaged among groups of animals (n = 5). The percentages of vessels with normal blood flow, slow blood flow and no blood flow were also calculated by dividing of number of vessels with normal blood flow, slow blood flow, and no blood flow (occluded vessels) by the total number of vessels recorded, respectively.
Histology
Animals were sacrificed 2 hours post-injection of fluorescencelabeled SSRBCs, and organs were collected and snap frozen in OCT media. Tissue section preparation was performed as previously described in detail [17] . Three random fields were imaged for each section of each organ, and fluorescence intensity for each field was quantified using ImageJ software. The values were averaged for the three fields to obtain mean fluorescence intensity. The mean fluorescence values were averaged among groups of animals (n = 3) for statistical analysis.
Flow cytometric analysis
Fluorescence-labeled sham-treated or MEK inhibitor-treated SSRBCs from a single donor were infused to TNFa-treated nude mice. Blood samples were collected 1, 10 and 20 min postinjection of SSRBCs and analyzed for the presence of human SSRBCs using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) [17] .
Statistical analysis
Results using sham and treated RBCs were compared only with results using the same donor sample, because SSRBC adhesion varies greatly among SCD patients [14] . Data were compared using parametric analyses (GraphPad Prism 5 Software, San Diego, CA), including repeated and non-repeated measures of analysis of variance (ANOVA). One-way and two-way ANOVA analyses were followed by Bonferroni corrections for multiple comparisons (multiplying the p value by the number of comparisons). A p value ,0.05 was considered significant.
Results
MEK inhibition inhibits SSRBC adhesion to endothelial cells in vitro
We have previously shown that ERK1/2 is abnormally activated in SSRBCs, but not in normal RBCs [18] . Because inflammation can initiate vasoocclusion [30] [31] [32] [33] , I first determined the relevance of SSRBC ERK1/2 inactivation in adhesion to TNFa-activated HUVECs in vitro. To inhibit ERK1/2, I used the MEK (kinase that directly activates ERK1/2) inhibitor, U0126, developed for animal use, and the MEK inhibitors, RDEA119, trametinib and AZD6244 developed for human use. The degree of adhesion of sham-treated SSRBCs to non-activated HUVECs varied from patient to patient (n = 7) and such variability in adhesion was unrelated to whether the patient was on hydroxyurea or not [14] . SSRBC adhesion was moderate (2761.7%; n = 4; Figure 1A ) to marked (60610.1%; n = 3; Figure 1B) Figures 1A and 1B) . Similarly, 100 nM U0126, RDEA119, AZD6244 or trametinib also decreased SSRBC adhesion to TNFa-activated HUVECs to levels below baseline adhesion of sham-treated SSRBCs to nonactivated HUVECs (p,0.0001 for each of the MEK inhibitors) ( Figures 1A and 1B) . In contrast, 10 mM damnacanthal, a highly potent and selective inhibitor of tyrosine kinase p56
Lck [34] , failed to inhibit SSRBC adhesion to TNFa-activated HUVECs ( Figure 1B) .
Because vascular bed is known to be involved in vasoocclusive pain crises, and prior to conduct our in vivo studies using nude mouse dorsal skin microvasculature, I next tested the effect of MEK inhibition on adhesion of human SSRBCs to human and mouse microvascular ECs, HMVECs-d and EOMA cells, respectively, non-treated or treated with TNFa, then washed. Less than 25% of non-treated SSRBCs adhered to non-activated HMVECs-d at a shear stress of 2 dynes/cm 2 ( Figure 1C ), and adhesion of these sickle cells increased significantly when HMVECs-d were treated with TNFa (p,0.0001). Treatment of SSRBCs with U0126 or RDEA119 again significantly inhibited adhesion of SSRBCs to TNFa-activated HMVECs-d to levels below baseline adhesion of SSRBCs to non-activated HMVECs-d (p,0.0001 for each inhibitor; Figure 1C ). However, basal normal RBCs (AARBCs) adherence to non-activated HMVECs-d was much lower than baseline adhesion of SSRBCs (p,0.0001), and treatment of HMVECs-d with TNFa did not support significant increased adhesion of AARBCs (p.0.05 compared to AARBC adhesion to non-activated HMVECs-d). In addition, although AARBCs adhered to some degree to TNFa-activated HMVECsd, U0126 had no effect on such adhesion ( Figure 1C) . Similar data were obtained when EOMA cells were used. SSRBCs adhered to some degree to non-activated EOMA cells at a shear stress of 2 dynes/cm 2 ( Figure 1D ). However, SSRBC adhesion to TNFa-activated EOMA cells increased by 2.260.09-fold over baseline SSRBC adhesion to non-activated EOMA cells (p,0.0001). U0126 or RDEA119 once more inhibited SSRBC adhesion to TNFa-activated EOMA cells to levels below baseline adhesion of sham-treated SSRBCs to non-activated EOMA cells (p,0.0001 for each inhibitor). In contrast, AARBCs adhered weakly to non-activated EOMA cells compared to basal adhesion of SSRBCs, and adhesion of AARBCs to TNFa-activated EOMA cells was slightly, but not significantly, up-regulated. The MEK inhibitor U0126 did not affect adhesion of these normal red cells to TNFa-activated EOMA cells ( Figure 1D ). Together, these data strongly suggest that MEK-dependent ERK1/2 inactivation in SSRBCs completely inhibits SSRBC adhesion to both nonactivated and activated microvascular endothelial cells, an effect that does not require increased activation of SSRBC ERK1/2.
MEK inhibition prevents SSRBCs from stimulating neutrophil adhesion in vitro
Patients with SCD have high counts of activated polymorphonuclear neutrophils (PMNs) [35] , and leukocytosis, in the absence of infection, correlates well with both clinical severity and vasoocclusion [35, 36] . I examined whether SSRBCs activate PMNs to adhere to ECs and whether MEK inhibitors prevent such effect. Washed sham-treated or MEK-inhibitor treated SSRBCs were co-incubated with isolated naïve PMNs prior to PMN adhesion assays. Naïve PMNs adhered to some degree to both HUVECs and HMVECs-d (1861% and 1462.2% adherent PMNs, respectively) at a shear stress of 1 dyne/cm 2 ( Figures 2A  and 2B ). PMN adhesion to HUVECs (n = 4) and HMVECs-d (n = 4) following PMN co-incubation with sham-treated SSRBCs, increased by a 2.760.2-fold (p,0.0001) and 360.5-fold (p, 0.0001), respectively, over baseline adhesion of naïve PMNs. However, SSRBC MEK inactivation with U0126, RDEA119, AZD6244 or trametinib inhibited the ability of SSRBCs to activate naïve PMN adhesion to either HUVECs or HMVECs-d, and PMN adhesion decreased to levels below baseline adhesion of native PMNs (p,0.0001 for each MEK inhibitor) (Figures 2A and  2B ). In contrast, AARBCs were not able to up-regulate PMN adhesion to HUVECs and HMVECs-d compared to adhesion of naïve PMNs ( Figure 2C ). These data suggest that SSRBC MEKdependent ERK1/2 inactivation completely prevents SSRBCs from stimulating PMN adhesion to microvascular endothelial cells.
Furthermore, to evaluate whether SSRBCs can also induce endothelial changes to support increased PMN adhesion, HUVECs were co-incubated with SSRBCs or AARBCs. After washing to eliminate non-adherent SSRBCs or AARBCs, adhesion to HUVECs of naïve PMNs not previously co-incubated with RBCs did not significantly increased compared to naïve PMN adhesion to HUVECs not co-incubated with RBCs (p.0.05, Figure 2D ). Naïve PMNs also adhered similarly to HUVECs coincubated with U0126-treated SSRBCs and HUVECs not coincubated with RBCs (p.0.05, Figure 2D ). We also evaluated whether SSRBC co-incubation with TNFa-treated HUVECs can affect adhesion of naïve PMNs to HUVECs. Naïve PMNs adhered strongly to TNFa-activated HUVECs compared to adhesion of PMNs to non-activated HUVECs (p,0.0001, Figure 2D ). After washing to eliminate non-adherent SSRBCs or AARBCs, no significant change in adhesion of naïve PMNs to TNFa-activated HUVECs was observed (p.0.05 compared to PMN adhesion to TNFa-activated HUVECs not co-incubated with RBCs, Figure 2D ). These data suggest that interactions of SSRBCs with endothelial cells failed to induce changes in endothelial cells to support increased PMN adhesion.
MEK inhibition reduces SSRBC adhesion to the vascular endothelium and vasoocclusion in vivo
These experiments were designed specifically to study the effect of MEK inhibitors on human SSRBC adhesion and vasoocclusion in vivo in the absence of the potential effect of these inhibitors on non-human RBCs, including murine RBCs, endothelium, leukocytes or platelets, and to determine whether SSRBC MEKdependent ERK1/2 inactivation has therapeutic potential in reducing RBC adhesion in vivo. Normal and SS human RBC preparations contained 0.2560.8610 6 /ml RBCs and 0.160.01610 6 /ml RBCs, respectively, and both showed unmeasurable (0 cells/ml) leukocytes or platelets, making it unlikely that human leukocytes and platelets could participate in SSRBC adhesion and vasoocclusion in my model. In addition, in these studies, the quantity of human RBCs infused to animals never exceed 10% of the total circulating RBCs, assuming that the mouse blood volume is 1.5 ml, thereby minimizing any possible rheological effects attributable to increased hematocrit [37] . RBCs in these small concentrations should also not influence vascular regulatory mechanisms or O 2 delivery.
To determine the therapeutic relevance of SSRBC MEK inactivation in vivo, human SSRBCs were sham-treated or treated with the MEK inhibitors, RDEA119 or U0126, ex vivo, washed, then adoptively transferred to nude mice previously treated with TNFa. Intravital microscopy observation of enflamed venules and arterioles visible through the dorsal skin-fold window chamber for at least 1 hour, showed that sham-treated human SSRBCs adhered to 7863% of vessels, both small and large, and arterioles with mean diameter = 2961.57 mm [ Figures 3A (panels 1, 2, 3 and 4) and 3D-E; Movie S1]. SSRBC adhesion occurred 1-4 min following SSRBC infusion, and progressively occluded microvessels at junctional and non-junctional points, and at curved and straight segments with evident blood stasis ( Figures 3A, 3F and 3G). In sharp contrast, RDEA119-treated SSRBCs demonstrated less frequent adhesion, which occurred in vessels much smaller in diameter than vessels supporting sham-treated SSRBC adhesion, with mean diameter no larger than 1361.32 mm [ Figures 3B  (panels 1, 2 and 3 ) and 3D-E; Movie S2]. Adhesion of RDEA119-treated SSRBCs was reduced by 88% compared to sham-treated SSRBCs (n = 5; p,0.0001) ( Figures 3A, 3B and 3D) . As a result of RDEA119 treatment, SSRBCs promoted occasional small vessel obstruction, and normal blood flow was restored in 8663.3% of vessels and arterioles recorded compared to 5065.5% of vessels with normal blood flow in animals infused with sham-treated cells (p,0.0001; Figures 3A, 3B, 3F and 3G ). The involvement of ERK1/2 in normal RBCs adhesion in vivo was also tested. Shamtreated and RDEA119-treated normal human RBCs showed no real adherence in enflamed vessels [ Figure 3C (panels 1, 2, 3 and 4); Movie S3], further confirming our previous data that ERK1/2 is inactived in normal RBCs [18] .
Similar anti-SSRBC adhesive benefit was obtained with U0126. (Figures 4A, 4B, 4E and 4F) . Together, these data strongly suggest that SSRBC MEK-dependent ERK1/ 2 inactivation effectively reduces vasoocclusion and restores normal blood flow in vessels by at least down-regulating SSRBC adhesive function.
MEK inhibition in SSRBCs reduces human SSRBC organ trapping
I examined the effect of MEK inactivation on human SSRBC trapping in organs typically affected and damaged in SCD, including the lungs, liver, spleen and kidneys. Trapping of shamtreated SSRBCs was extensive in the lungs, liver and spleen ( Figures 5A and 5B) . However, treatment of SSRBCs with RDEA119 significantly decreased human SSRBC sequestration in the lungs, liver, and spleen. SSRBC trapping in the kidneys was (Figures 5A and 5B ). This suggests that MEKdependent ERK1/2 inhibition in SSRBCs reduces SSRBC organ trapping, which may in fact result in reduced organ damage in SCD.
MEK inhibition in SSRBCs increases the number of human SSRBCs in bloodstream
The effect of MEK inhibition on human SSRBCs in circulation in vessels and arterioles of animals was also examined. The percentage of sham-treated human SSRBCs that did not adhere to the vascular walls and remained circulating in bloodstream of animals decreased over time ( Figure 6 ). However, RDEA119-treated human SSRBCs circulating in vessels and arterioles of animals, was higher than sham-treated SSRBCs, and did not decrease over time. The percentage of RDEA119-treated SSRBCs in bloodstream 10 min post-infusion of SSRBCs was 2.1-fold higher than sham-treated SSRBCs [p,0.05 for RDEA119-treated vs. sham-treated at 10 min or 20 min]. These data indicate that inhibition of MEK-dependent ERK1/2 signaling is associated with an increase in the number of SSRBCs circulating in vessels and arterioles of animals compared to sham-treated cells, and strongly argue that such increase in the number of MEK inhibitortreated SSRBCs circulating in bloodstream reflects the fact that these sickle cells did not adhere to the vascular endothelium and were not trapped in organs.
Discussion
Acute painful vasoocclusive crises caused largely by sickle red cell adherence [38] [39] [40] in patients with SCD, remain a major scientific challenge that invites conceptually new approaches. I now provide a potential new therapeutic alternative to reduce acute vasoocclusive crises. Recently, we have discovered that although MEK and ERK1/2 are highly expressed in both SSRBCs and normal RBCs, ERK1/2 is abnormally activated only in SSRBCs, but not in normal RBCs [18] . To determine the therapeutic potential of SSRBC MEK-dependent ERK1/2 signaling inactivation, I have selectively targeted MEK using I observed SSRBC adhesion occurring both in enflamed vessels, predominantly in small and large postcapillary venules promoting vasoocclusion, and in arterioles [41] . Because only SSRBCs, but not normal RBCs, adhered to both activated human and murine microvascular endothelial cells in vitro (Figure 1 ) and in vivo (Figure 3) , interactions between human SSRBCs and murine endothelium in vivo were not due to non-specific binding or TNFa effect on SSRBC adherence, since treatment of SSRBCs with TNFa failed to increase SSRBC adhesion to endothelial cells in vitro (data not shown). I also recognize that the characteristics of endothelial cells and microcirculatory beds vary among different tissues; it remains to be determined whether SSRBC adhesion is equally avid in all tissues. In addition, my model represents an appropriate system for identifying the effect of signaling mechanisms in SSRBCs involved in adhesion and vasoocclusion in vivo, since it allows for the manipulation of RBCs exclusively, while still allowing study of adhesion and vasoocclusion in an intact vasculature, in the context of physiologic blood flow and shear stresses, and where vessels were non-instrumented and contralateral to the window chamber.
Numerous mechanisms of SSRBC adhesion to endothelium and vasoocclusion have been demonstrated in in vitro and ex vivo models, but there are only limited data regarding the contribution of specific factors initiating or inducing those interactions in vivo. Studies have previously shown that human SSRBCs adhere to human, murine and rodent endothelial avb3 [14, 17, 42, 43] . There is also a growing body of data showing that activated monocytes [33] and PMNs [44] adhere to endothelial cells in SCD. Turhan et al. for instance have demonstrated in transgenic sickle mice that murine SSRBCs can bind to adherent leukocytes in inflamed cremasteric vessels, producing vasoocclusion [30] . In my animal model, administration of TNFa to nude mice prior to SSRBC infusion activates murine neutrophil adherence to the endothelium. It is therefore possible that SSRBCs adhered to both activated endothelial cells and leukocytes promoting vasoocclusion, and MEK inhibitors may affect SSRBC-vascular endothelium and SSRBC-leukocyte interactions, and subsequent vasoocclusion. I further surmise that MEK inhibitors may alleviate vascular and organ injuries at the site of SSRBC-induced vasoocclusion, since these inhibitors reduced both SSRBC adhesion and SSRBC organ trapping; an effect associated with enhanced SSRBC fraction circulating in bloodstream.
Furthermore, MEK inhibitors have the potential to prevent SSRBCs from activating neutrophils to adhere to endothelium. While SSRBCs stimulated adhesion of naïve neutrophils to nonactivated endothelial cells, normal RBCs failed to activate naïve PMN adherence. Increased PMN adhesion is unlikely to be caused by SSRBC-induced endothelial changes, which can occur in response to contact with SSRBCs [45] , because contact of SSRBCs with non-activated or TNFa-activated ECs failed to cause increased adhesion of naïve PMNs to ECs ( Figure 2D ). In addition, hypotonic lysis of SSRBCs prior to PMN adhesion assays did not lower adhesion of PMNs to non-activated ECs (data not shown). These data are in concordance with our previous data showing that human SSRBCs are able to increase adhesion of monocytes and lymphocytes to ECs in vitro [16] , and murine leukocytes to the vascular endothelium in nude mice in vivo [17] . My data now further show that SSRBCs' ability to activate PMN adhesion to ECs was completely inhibited by 4 different MEK inhibitors. I therefore suggest that abnormal MEK-dependent ERK1/2 activation in SSRBCs could contribute to the pathophysiology of SCD by activating a secondary cellular process: neutrophil adherence to the endothelium. Previous studies have also shown that activated neutrophils can increase SSRBC adhesion to lung vascular endothelium [46, 47] . It is therefore possible that activated neutrophils may affect SSRBC adhesiveness by enhancing SSRBC ERK1/2 activation, a mechanism yet to be defined.
Activation and adherence of PMNs could induce production of multiple cytokines, including TNFa, IL-8 and IL-1b, that activate the vascular endothelium, resulting in up-regulation of cellular ligands, including intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), for blood cell adhesion molecules. Such processes could further enhance the adhesiveness of inflammatory cells, platelets and SSRBCs to endothelium [48] , as well as further tissue damage. These events collectively could be followed by activation of both coagulation cascade as evidenced previously by elevated plasma levels of thrombin-antithrombin (TAT) complexes, prothrombin fragment 1.2 (F1.2), and D-dimer [49, 50] , as well as increased platelet activation [51] in patients with SCD, all of which contribute to a systemic hypercoagulable state [52] , and inflammatory pathways.
In summary, anomalous MEK-dependent ERK1/2 activation in SSRBCs can contribute to the pathogenesis of SCD by potentially activating at least two significant cellular players of vasoocclusive events, SSRBC adhesion and SSRBC-induced activation of leukocytes. Thus, MEK inhibitors could have a novel multi-facetted therapeutic application for acute vasoocclusive episodes, and my data are a formidable initial step towards testing of existing MEK inhibitors, such as RDEA119 and the FDA-approved trametinib in SCD.
Supporting Information
Movie S1 Adhesion of sham-treated human SSRBCs in vivo. Movies were merged to show SSRBC circulatory behavior in the vasculature at different locations and over time. Sham-treated SSRBCs showed extensive adhesion in postcapillary vessels and arterioles, and progression of vasoocclusion occurred within the first 2 to 3 minutes following human SSRBC infusion, which resulted in permanent blockade of some venules both at junctions and straight segments causing blood flow stasis. 
